

CLL Global Virtual Town Hall

**Thank you for your patience.
We will begin shortly.**

- Have questions for our panel?
- Please email them to townhall@cllglobal.org



• CHRONIC LYMPHOCYTIC LEUKEMIA •

Questions?

Please send an email to townhall@cllglobal.org

A video of today's Town Hall presentation will be available at our website www.cllglobal.org



• CHRONIC LYMPHOCYTIC LEUKEMIA •

Dr. William Wierda

President & CEO

CLL Global Research Foundation

**Jane and John Justin Distinguished Chair in Leukemia
Research in Honor of Dr. Elihu Estey**

Executive Medical Director

The University of Texas MD Anderson Cancer Center



• CHRONIC LYMPHOCYTIC LEUKEMIA •

Dr. Patrick Reville

Assistant Professor in the Department of Leukemia
The University of Texas MD Anderson Cancer Center



• CHRONIC LYMPHOCYTIC LEUKEMIA •

ASH 2023 CLL Review

07 FEB 2024

First-line CLL Treatment

- Long-term (10-yr) ibrutinib outcomes (#201 Wiestner)
- ELEVATE-TN 6-yr (#636 Sharman)
- GAIA 4-yr follow up (#635 Furstenau)
- CAPTIVATE FD 5-yr follow up (#633 Ghia)
- GLOW 57-mo follow up (#634 Follows)
- FLAIR (IBR+VEN vs. FCR) (#631 Hillmen)

Relapsed / Refractory CLL Treatment

- **APLINE (ZANU vs. IBR) (#202 Brown)**
- **CLL2-BAAG (AVO) (#203 Furstenau)**
- **Pirtobrutinib after cBTKi (#325 Woyach)**
- **Pirtobrutinib BTK mutations (#326 Brown)**
- **Phase I/II Liso-cel (CD19-CAR-T cells) (#330 Siddiqi)**
- **Phase I LP-168 (ncBTKi) (#328 Woyach)**
- **Phase I NVG-111 (Ror1 bispecific) (#329 Jasani)**

Richter Transformation

- **Tislelizumab (PD1 mAb) + Zaunbrutinib (#204 Al-Sawaf)**

MDACC Active Trials for First-line CLL

Investigator-initiated Studies

- ncBTKi + BCL2i + CD20 (PIRTO + VEN + OBIN) (Ph II)
- BCL2i + CD20 + PD-L1 (VEN + OBIN + ATEZO) (Ph II)
- Fixed-duration cBTKi + CD20 (ZANU + RIT) (Ph II)
- Fixed-duration cBTKi + CD20 (ACA + OBIN) (Ph II)

MDACC Relapsed / Refractory CLL

- **New drugs – established targets**

- BTK degraders (ProTac; NX-5948) (ABBV-101)
- CD3xCD20 bi-specific (mosunetuzumab; epcoritamab) (Ph I)
- ncBTKi (AS-1763) (Ph I)
- BCL2i+CD20 ± ncBTKi (VEN+OBIN ± PIRTO) (Ph III)
- BCL2i+cBTKi ± CD20 (ACA+VEN ± OBIN) (Ph II)
- BCL2i for consolidation with BTKi (VEN) (Ph II)
- ncBTKi for consolidation with VEN (PIRTO) (Ph II)

- **New targets – new drugs**

- MALT1i (ABBV-525) (Ph I)
- MCL-1/CDK9 – (Fadraciclib, CYC065) (Ph I)
- BCL-xLi+BCL-2i – (LP118) (Ph I)

MDACC Active Trials for Richter's Transformation

- ncBTKi + BCL2i + CD20 (PIRTO + VEN + OBIN) (Ph II)
- BCL2i + CD20 + PD-L1 (VEN + OBIN + ATEZO) (Ph II)
- BCL-xLi+BCL-2i – (LP118) (Ph I)
- BCL2i + CIT (VEN + R-CHOP) (Ph II)
- CD19-CAR-T cells (off the shelf FT819 +Zuma-25) (Ph I)

Q&A



Send questions to
townhall@cllglobal.org



• CHRONIC LYMPHOCYTIC LEUKEMIA •

Thank You For Joining!

Contact Us



Sam Pace
townhall@cllglobal.org
(713) 745-1861



Visit our website at cllglobal.org
to view slides from today's presentation



Follow us on Facebook at facebook.com/cllglobal
to keep up with the latest **CLL news**



CLL Global Research Foundation
P.O. Box 301402, Unit 428
Houston, Texas 77230